Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047334 | 0.90 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL6047213 | 0.88 | ADORA2A (0.82) | ADORA2A | |
| SCHEMBL6047316 | 0.88 | ADORA2A (0.78) | ADORA2A | |
| SCHEMBL6047311 | 0.88 | ADORA2A (0.78) | ADORA2A | |
| SCHEMBL8275682 | 0.85 | ADORA2A (0.78) | ADORA2A | |
| SCHEMBL6047180 | 0.83 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL6047172 | 0.83 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL6047267 | 0.83 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL6047386 | 0.83 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL7430360 | 0.82 | ADORA2A (0.56) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295047-A2 | Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders | Schering Corporation (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2269596-A2 | Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders | Schering Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1578409-B1 | USE OF ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATMENT OR PREVENTION OF EXTRA-PYRAMIDAL SYNDROME | SCHERING CORP (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090029967-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION | 2009-01-29 | — | — | US | disclosed |
| US-20090029967-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION | 2009-01-29 | — | — | US | disclosed |
| US-7414058-B2 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007047293-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007038212-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1544200-A1 | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | SCHERING CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029967-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885 |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885 |
| US-20040138235-A1 | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.